Following in vitro studies that supported CTLA-4 as a key checkpoint molecule in the antitumor immune response, anti-CTLA-4 blocking antibody therapy was initially tested in numerous animal models including breast[51], prostate[52], lymphoma[53], colon[54] and melanoma[55]. The gene discussed is CTLA4; the disease is melanoma.